ACE-031
Status
No approved product. No FDA-approved product exists, and no approval elsewhere is listed in this site's sources. An investigational myostatin inhibitor whose clinical development was halted.
What it is
A myostatin-pathway molecule whose trials were stopped for safety findings.
What published research measured
Clinical development was discontinued after nosebleeds and gum bleeding were reported in trials, alongside dilated blood vessels.
Caution
No FDA-approved product exists, and no approval elsewhere is listed in this site's sources. An investigational myostatin inhibitor whose clinical development was halted.
Source
Campbell C et al. 2017 — Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, p… · Attie KM et al. 2013 — A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers · Cadena SM et al. 2010 — Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.